GCP
ESPR icon

GSA Capital Partners’s Esperion Therapeutics ESPR Stock Holding History

GSA Capital Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,549
Closed -$46K – 1847
2025
Q4 		$46K Sell
12,549
-26,462
-68% -$85.5K ﹤0.01% 1577
2025
Q3 		$103K Buy
+39,011
New +$75.5K 0.01% 1522
2025
Q1 		– Sell
-94,917
Closed -$209K – 1770
2024
Q4 		$209K Buy
+94,917
New +$221K 0.02% 1394
2024
Q3 		– Sell
-813,399
Closed -$1.81M – 1713
2024
Q2 		$1.81M Buy
813,399
+364,270
+81% +$857K 0.13% 185
2024
Q1 		$1.2M Sell
449,129
-679,020
-60% -$1.65M 0.1% 325
2023
Q4 		$3.37M Buy
1,128,149
+11,494
+1% +$14.9K 0.28% 21
2023
Q3 		$1.09M Buy
1,116,655
+685,733
+159% +$992K 0.09% 351
2023
Q2 		$599K Buy
430,922
+318,338
+283% +$444K 0.06% 630
2023
Q1 		$179K Buy
112,584
+94,367
+518% +$487K 0.02% 1277
2022
Q4 		$113K Buy
+18,217
New +$130K 0.01% 1289
2021
Q4 		– Sell
-23,628
Closed -$285K – 1509
2021
Q3 		$285K Buy
+23,628
New +$344K 0.03% 1057
2021
Q1 		– Sell
-20,093
Closed -$522K – 1211
2020
Q4 		$522K Buy
20,093
+7,043
+54% +$211K 0.09% 407
2020
Q3 		$485K Buy
+13,050
New +$517K 0.08% 408
2019
Q3 		– Sell
-15,197
Closed -$707K – 1478
2019
Q2 		$707K Buy
+15,197
New +$714K 0.08% 449
2017
Q4 		– Sell
-9,050
Closed -$454K – 1624
2017
Q3 		$454K Sell
9,050
-655
-7% -$31.6K 0.03% 1023
2017
Q2 		$449K Sell
9,705
-26,623
-73% -$979K 0.03% 1060
2017
Q1 		$1.28M Buy
+36,328
New +$832K 0.07% 499
2015
Q4 		– Sell
-31,898
Closed -$752K – 1854
2015
Q3 		$752K Buy
31,898
+23,198
+267% +$1.46M 0.04% 860
2015
Q2 		$711K Buy
+8,700
New +$852K 0.03% 1133

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's ESPR Position: Q1 2026 in Review

GSA Capital Partners sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 12,549 shares — an estimated $46K sold.

GSA Capital Partners first reported a position in ESPR in Q2 2015 and held it in 19 quarters. The position peaked at $3.37M in Q4 2023. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • GSA Capital Partners reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 12,549 Esperion Therapeutics shares in Q1 2026, an estimated $46K.
  • GSA Capital Partners first reported a position in Esperion Therapeutics in Q2 2015 and held it in 19 quarters.
  • GSA Capital Partners's Esperion Therapeutics position peaked at $3.37M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.